These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 20102746)
1. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Perkins J; Field T; Kim J; Kharfan-Dabaja MA; Fernandez H; Ayala E; Perez L; Xu M; Alsina M; Ochoa L; Sullivan D; Janssen W; Anasetti C Biol Blood Marrow Transplant; 2010 Jul; 16(7):937-47. PubMed ID: 20102746 [TBL] [Abstract][Full Text] [Related]
2. Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention. Hamilton BK; Rybicki LA; Li H; Lucas T; Corrigan D; Kalaycio M; Sobecks R; Hanna R; Rotz SJ; Dean RM; Gerds AT; Jagadeesh D; Brunstein C; Sauter CS; Copelan EA; Majhail NS Blood Adv; 2023 Aug; 7(16):4505-4513. PubMed ID: 37352262 [TBL] [Abstract][Full Text] [Related]
3. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491 [TBL] [Abstract][Full Text] [Related]
4. Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate/Tacrolimus. Ashouri K; Fernandez E; Ginosyan A; Feliciano CM; Hom B; Rodman J; Ali A; Ladha A; Woan K; Tam E; Chaudhary P; Yaghmour G Transplant Proc; 2024 Sep; 56(7):1671-1677. PubMed ID: 39174390 [TBL] [Abstract][Full Text] [Related]
5. High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. Al-Kadhimi Z; Gul Z; Chen W; Smith D; Abidi M; Deol A; Ayash L; Lum L; Waller EK; Ratanatharathorn V; Uberti J Biol Blood Marrow Transplant; 2014 Jul; 20(7):979-85. PubMed ID: 24709007 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216 [TBL] [Abstract][Full Text] [Related]
7. Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation. Miyamoto T; Takashima S; Kato K; Takase K; Yoshimoto G; Yoshida S; Henzan H; Osaki K; Kamimura T; Iwasaki H; Eto T; Teshima T; Nagafuji K; Akashi K Int J Hematol; 2017 Jan; 105(1):92-99. PubMed ID: 27686673 [TBL] [Abstract][Full Text] [Related]
8. The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors. Yerushalmi R; Shem-Tov N; Danylesko I; Shouval R; Nagler A; Shimoni A Am J Hematol; 2017 Mar; 92(3):259-268. PubMed ID: 28052467 [TBL] [Abstract][Full Text] [Related]
9. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481 [TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777 [TBL] [Abstract][Full Text] [Related]
11. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide. Elmariah H; Otoukesh S; Kumar A; Ali H; Arslan S; Shouse G; Pourhassan H; Nishihori T; Faramand R; Mishra A; Khimani F; Fernandez H; Lazaryan A; Nieder M; Perez L; Liu H; Nakamura R; Pidala J; Marcucci G; Forman SJ; Anasetti C; Locke F; Bejanyan N; Al Malki MM Transplant Cell Ther; 2024 Feb; 30(2):229.e1-229.e11. PubMed ID: 37952648 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft Versus Host Disease Prophylaxis After Allogeneic Hematopoietic Cell Transplantation. Huang B; Lin X; Zhang Z; Zhang Y; Zheng Z; Zhong C; He X; Chen M Transplantation; 2020 Feb; 104(2):428-436. PubMed ID: 31283681 [TBL] [Abstract][Full Text] [Related]
13. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia]. Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123 [TBL] [Abstract][Full Text] [Related]
14. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Snyder DS; Palmer J; Gaal K; Stein AS; Pullarkat V; Sahebi F; Vora N; Nakamura R; Forman SJ Biol Blood Marrow Transplant; 2010 Feb; 16(2):281-6. PubMed ID: 19786111 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors + Mycophenolate Mofetil versus Sirolimus + Mycophenolate Mofetil. Esquirol A; Pascual MJ; Montoro J; Piñana JL; Ferrà C; Herruzo B; Garcia-Cadenas I; Balaguer A; Perez A; Huguet M; Redondo S; Villalba M; Hernandez-Boluda JC; Chorao P; Hernani R; Sanz J; Solano C; Sierra J; Martino R Transplant Cell Ther; 2024 Oct; 30(10):1025.e1-1025.e14. PubMed ID: 39116938 [TBL] [Abstract][Full Text] [Related]
16. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223 [TBL] [Abstract][Full Text] [Related]
17. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation]. Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492 [TBL] [Abstract][Full Text] [Related]
18. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Nagler A; Labopin M; Swoboda R; Schroeder T; Hamladji RM; Griskevicius L; Salmenniemi U; Rambaldi A; Mielke S; Kulagin A; Passweg J; Luft T; Gedde-Dahl T; Forcade E; Helbig G; Stelljes M; Castilla-Llorente C; Spyridonidis A; Brissot E; Ciceri F; Mohty M Bone Marrow Transplant; 2024 Jul; 59(7):1012-1021. PubMed ID: 38615143 [TBL] [Abstract][Full Text] [Related]
19. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Piñana JL; Valcárcel D; Fernández-Avilés F; Martino R; Rovira M; Barba P; Martínez C; Brunet S; Sureda A; Carreras E; Sierra J Bone Marrow Transplant; 2010 Sep; 45(9):1449-56. PubMed ID: 20140024 [TBL] [Abstract][Full Text] [Related]
20. Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. Terakura S; Wake A; Inamoto Y; Murata M; Sakai R; Yamaguchi T; Takahashi S; Uchida N; Onishi Y; Ohashi K; Ozawa Y; Kanamori H; Yamaguchi H; Fukuda T; Ichinohe T; Takanashi M; Atsuta Y; Teshima T Bone Marrow Transplant; 2017 Mar; 52(3):423-430. PubMed ID: 27941766 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]